



PANPHARMA
INJECTING LIFE

Panpharma UK

Carbon Reduction Plan

Publication Date: 19th June 2024

Document History

Document Version	Revision Date	Revision Details
01	19/06/2024	New document

Panpharma UK
3 Southport business Park
Wight Moss Way
Southport
PR8 4HQ

Managing Director
Pierre Moysan

Registered in England
Company Number: 9519853
Vat GB 225252631

Contents

Publication Date: 19 th June 2024.....	1
1 Commitment to achieving Net Zero	3
2 Emission Reporting – Baseline and Current Reporting Year (2022).....	3
Scope 1 and 2	4
Scope 3.....	4
3 Emission Reduction Targets.....	5
3.1 General	5
3.2 Scope 1 and 2 Emissions	5
3.3 Scope 3 Emissions.....	5
3.4 Emission Reduction Projection	5
4 Carbon Reduction Initiatives	6
4.1 Completed Carbon Reduction Initiatives.....	6
4.2 Future Carbon Reduction Initiatives	6

1 Commitment to achieving Net Zero

Panpharma UK is committed to reducing its carbon footprint to support public health and global sustainability efforts. This program outlines strategies and actions to achieve Net Zero emissions by 2045 in line with NHS expectations.

2 Emission Reporting – Baseline and Current Reporting Year (2022)

Following its carbon footprint calculation for 2022, Panpharma UK has decided to use 2022 emissions as the baseline going forward. Panpharma UK used the same platform as its parent company to undertake an initial carbon footprint for the UK subsidiary.

Panpharma France is carrying out its 3rd carbon footprint update this year (2024). Panpharma was a pioneer in France, along with 9 other pharma companies, partnering with the LEEM (French Pharma syndicate) and the WECOUNT company. WECOUNT specialises in supporting companies in many different sectors to complete their carbon footprint analysis and develop improvement plans to support the trajectory to Net Zero.

As a result, Panpharma France reduced its carbon footprint by 25% between 2021 and 2022 showing the company commitment to reduce its global impact (ISO 14001 certification since 2015). For the last 2 years the company has produced its Extra Financial Report (CSR) and will move to the new CSRD regulation in 2025.

WECOUNT platform (<https://www.wecount.io/>) use emission reporting methodologies that complies with:



International Carbon Reporting Standard



Greenhouse Gas Protocol
International Carbon Reporting Standard



Bilan Carbone de l'ABC
Bilan Carbone Association



Bilan des Gaz à Effets de Serre réglementaire (BEGES)

Mandatory every 4 years for companies >500 peoples, on Scope 1 and 2, Scope 3 from 01/23 onwards

The 2022 baseline emissions data is the reference point against which future reductions in emissions will be measured.

Baseline year: 2022	
Additional details relating to the baseline emissions calculations	
<p>The below data is the result of collecting consumption and spend data, researching emission factors and calculating the carbon emissions using the WECOUNT Platform as we did for Panpharma France</p> <p>Panpharma UK has decided to include more categories for scope 3.</p> <p>Our entity in UK is made up of 2 employees, based in Southport, with rented offices: address 3 Southport Business Park, Wight Moss Way, Southport, Merseyside, PR8 4HQ.</p> <p>Given the size of our structure in UK we have decided to group Scope 1 and 2 as the tCO₂e is not significant.</p>	
Baseline year 2022 emissions:	
Emission category	Total (tCO ₂ e)
Scope 1 & Scope 2:	0.065 (0.04%)
Scope 3:	146.63 (99.96%)
<i>Upstream transportation and distribution</i>	<i>137.4 (93.7%)</i>
<i>Waste generated in operations (offices)</i>	<i>0.1 (0.1%)</i>
<i>Business travel</i>	<i>1.17 (0.8%)</i>
<i>Employee commuting</i>	<i>1.57 (1.1%)</i>
<i>Downstream transportation and distribution</i>	<i>4.29 (2.9%)</i>
<i>Food (lunch meals for employee)</i>	<i>0.96 (0.7%)</i>
<i>Building (rented offices)</i>	<i>0.7 (0.5%)</i>
<i>IT equipment and office consumables</i>	<i>0.34 (0.23%)</i>
Total emissions:	146.7 (100%)

Scope 1 and 2

Electricity of the rented facility for our 2 people based in Southport is the only source of CO₂ in scope 1 and 2, as there are no fleet or leased vehicles in operation.

Scope 3

Minimum NHS requirement scopes have been included (upstream, waste in operations, business travel, employee commuting and downstream transportation and distribution)

Our downstream impact is based on data from our transport and distribution provider (Mawdsleys). It is calculated on the 'Top down' basis agreed between the NHS, APBI, BGMA and HDA, which uses an average CO₂e per pack calculation for 2022.

We have covered several sections in addition to the current minimum NHS requirements:

- Emissions linked with lunch (even if this is prepared at home and not coming from the company). Related norms categories BEGES 4.1 / GHG 3.1 / ISO 4.1

- Waste treatment generated by our employee. Related norms categories BEGES 4.3 / GHG 3.5 / ISO 4.3
- Office furniture. Related norms categories BEGES 4.2 / GHG 3.2 / ISO 4.2
- Building (rented). Related norms categories BEGES 4.2 / GHG 3.2 / ISO 4.2

3 Emission Reduction Targets

3.1 General

To continue its progress to achieving Net Zero and in line with the NHS goals, Panpharma UK has adopted the following carbon reduction targets:

- (1) For the emissions Panpharma UK control directly we aim to reach Net Zero by 2035.
- (2) For the emissions Panpharma UK can influence we aim to reach Net Zero by 2045.

3.2 Scope 1 and 2 Emissions


Given the size of our UK based office (2 people and 32.4 m²) the tCO₂e is deemed exceptionally low and is judged as not significant.

3.3 Scope 3 Emissions

To achieve Net Zero, Panpharma UK intend to reduce scope 3 emissions to zero by 2045 and we propose for the moment a linear decrease. This will be adapted at the same time that key opportunities for improvement are identified. This will be also impacted by our partners as the main impact of our CO₂ emission is coming from upstream and downstream transportation.

3.4 Emission Reduction Projection

Scope 1 & 2, given the size, are not considered in the projection graph which focuses on our Scope 3 reduction projections.



Panpharma UK will also adapt the indicator if future iterations give more data on scope 3 emissions.

4 Carbon Reduction Initiatives

4.1 Completed Carbon Reduction Initiatives

In 2022, Panpharma UK moved offices from Liverpool to Southport which had a positive impact on our impact from our employee commuting aspect achieving a full year impact of a 58% reduction.

Staff are encouraged to use Microsoft Teams to conduct online meetings to reduce business travel. In 2022 we recorded only four business trips using flights (for 1 person) showing the effectiveness of this policy.

4.2 Future Carbon Reduction Initiatives

4.2.1 Reduce Scope 1 & 2 Emissions

We will continue to discuss with our office owner initiatives to be carbon neutral in this scope.

Lighting

Panpharma UK has passive infra-red sensors in the office to ensure the lights are only on when the office is in use. LED lights are in operation in parts of the office building, with plans to collaborate with the property owner to ensure LED lights are used throughout the whole office.

4.2.2 Reduce Scope 3 Emissions

Upstream and downstream transportation

We will continue to work with our distribution partner, Mawdsley Brooks, to identify together approaches to reduce impact. For example, the use of more electric vehicles and carbon off-setting schemes.

Panpharma will review current internal group transportation procedures to challenge the groupage shipment options.

Digitalization / E-invoicing

Panpharma Group is working on the implementation of a fully digitized P2P (Procure to Pay) system and Panpharma UK will be included in the roll out.

Eco friendly paper

Review of currently used paper and where possible, switching to more environmentally friendly options.

Printing policy

IT policy under review to set out guidelines for printing of documents (e.g., black/white vs colour, double-sided) to reduce the amount of paper usage.

4.2.3 Other Initiatives

Environmental Awareness

Training

Panpharma is ISO 14001 certified since 2015 and to continue to improve, we plan to roll out climate change awareness training to all staff to increase the understanding of the challenge ahead, not only as a company but also as a citizen.

Carbon Offsetting Schemes

Panpharma Group is starting to look at ways to offset a part of its CO₂ impact and this will include Panpharma UK.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the Managing Directors.

On behalf of Panpharma UK

Luitré, 19th June 2024



Pierre MOYSAN
Managing Director